EP05.02-008 Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer

Icotinib is a novel and selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) for oral usage. Adjuvant therapy with icotinib has been confirmed to be associated with the improvement of DFS among patients with EGFR-mutant non-small-cell lung cancer (NSCLC) in several studies. However, the clinical benefit of neoadjuvant icotinib combined with chemotherapy for EGFR-mutant NSCLC remains unknown. This is the first trial evaluating the efficacy and safety of icotinib plus chemotherapy as neoadjuvant therapy for patients with stage II-IIIB EGFR-mutant NSCLC.